Selective targeting and reprogramming of leukocytes using fully degradable nanomedicines
The Peer’s lab work at the interface of materials science, chemistry, molecular biology, and immunology, to discover and validate novel therapeutic targets at the molecular level, and to develop specific molecular medicines for therapeutics and disease management.
The lab is highly dynamic, multidisciplinary, and focuses on developing targeted vehicles for cell-specific delivery of novel molecular medicines (e.g. RNAi , mRNA, saRNA, DNA and novel genome editing strategies). The lab goal is to translate academic discoveries into innovative therapeutic modalities. With that in mind, Prof. Peer also founded SPARK Tel Aviv to accelerate cures via academic discoveries. Prof. Peer strives to develop the career of young students and encourage them to fulfill their ambitions and dreams.